Market Overview

UPDATE: Bank of America Downgrades Dr. Reddy's Laboratories to Neutral on Modest Outlook

Related RDY
Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield
Celgene's Vidaza Disappoints In Phase III Study - Analyst Blog

Bank of America downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Buy to Neutral with a $36.72 price objective.

Bank of America noted, "Following recent outperformance (vs BSE Healthcare), we downgrade DRL from Buy to Neutral with a revised PO of Rs1975. This factors (1) higher mkt share from recent US launches, reflected in slight increase in core profit estimates, partially offset by (2) sharp cut in exclusivities driving reduction in NPV to Rs25 (vs Rs70 earlier). We expect multiples to be capped due to modest growth prospects (12% profit CAGR), below historic growth and peers."

Dr Reddy's Laboratories closed at $35.76 on Thursday.

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (RDY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free